Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clenbuterol in Spinal and Bulbar Muscular Atrophy
NCT06169046Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal and bulbar muscular atrophy (SBMA) comparing Clenbuterol with Placebo (2 arms). Primary endpoint: 6-Minute Walk Test at 48 weeks. Started Apr 2024; status: recruiting.
02
Drugs
clenbuterol
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on NCT06169046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169046.